Replies to post #222225 on Amarin Corp Plc (AMRN)

[Lemmiwinks]

The more the board digresses into nonsense and “what ifs”..... the more likely the simplest and most likely outcome will be. 100% chance of desired >135 TG indication in my opinion. 65% chance of something better........and in among those possibilities, is the “holy of holy’s”.....the just give it to everyone!!!!! All possibilities already have and will happen....let’s hope we are in the most rational (as we see it) reality/universe.
Lemmi

[Condor64]

The discussion started in connection with trying to think through how much merit is in the generics' argument that they aren't inducing infringement because they aren't encouraging use for 12+ weeks.

It makes sense to me that, because CVD is unquestionably a chronic condition, then a label indicating treatment of CVD would implicitly be encouraging use for 12+ weeks.

Your question ("Is not the treatment of a hypertriglyceride indication always a subset of treatment of any CVD indication?") is a good one I don't know the answer to. If yes, that would be a good fact for AMRN. But doesn't the fact that AMRN's expert admitted to prescribing V for <12 weeks 5% of the time (which led to the finding of no contributory) suggest otherwise in at least some cases?

[sts66]

Is not the treatment of a hypertriglyceride indication always a subset of treatment of any CVD indication?

Depends on who you ask - many medical organizations believe the answer is "yes", but in 2013 the FDA said the answer was "no". R-IT data shows CVD risk reduction is almost independent of TG level reduction, so the real answer is probably "maybe".